Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoGen has initiated clinical testing with its developmental compound huN901-DM1, for the treatment of multiple myeloma, or cancer of the bone marrow. The compound is also in two separate clinical trials for the treatment of small-cell lung cancer.
Subscribe to our email newsletter
The primary objective of the phase I study is to evaluate the safety of huN901-DM1 in patients with relapsed or refractory multiple myeloma, and to identify the maximum tolerated dose of the compound in this patient population. The study also will evaluate the anticancer activity of huN901-DM1 in multiple myeloma.
The first dose level to be evaluated in this study will be close to the maximum tolerated dose that was established with the compound as part of the small-cell lung cancer clinical program. Patients will receive huN901-DM1 – as monotherapy – once weekly for two consecutive weeks every three weeks.
“HuN901-DM1 is a targeted approach to the treatment of multiple myeloma, in contrast to the currently approved agents for this malignancy,” commented Dr Schlossman, the principle investigator of the study. “The findings from the preclinical multiple myeloma studies are encouraging, and we look forward to assessing this compound clinically.”
HuN901-DM1 is in development by ImmunoGen for the treatment of cancers that express the CD56 protein targeted by the compound. CD56-expressing malignancies include multiple myeloma, small-cell lung cancer, and other cancers of neuroendocrine origin.